Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3053% below fair value
$1.67+0.15 (+9.87%)
Close on Nov 18, 2026Market cap $102.90MP/E –Yield –
Voyager Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Voyager Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$121.42M. For fiscal 2025 it was -$135.06M. The highest annual figure on record is $74.66M in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$135.06M | – |
| FY2024 | Dec 31, 2024 | -$18.83M | -125.2% |
| FY2023 | Dec 31, 2023 | $74.66M | – |
| FY2022 | Dec 31, 2022 | -$15.00M | – |
| FY2021 | Dec 31, 2021 | -$55.13M | – |
| FY2020 | Dec 31, 2020 | -$108.81M | -365.7% |
| FY2019 | Dec 31, 2019 | $40.95M | – |
| FY2018 | Dec 31, 2018 | -$20.19M | – |
| FY2017 | Dec 31, 2017 | -$65.34M | – |
| FY2016 | Dec 31, 2016 | -$47.51M | -218.0% |
| FY2015 | Dec 31, 2015 | $40.27M | – |
| FY2014 | Dec 31, 2014 | -$14.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$25.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.89M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$38.55M | -168.1% |
| Q4 FY2024 | Dec 31, 2024 | -$14.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.55M | – |
| Q1 FY2024 | Mar 31, 2024 | $56.63M | -54.0% |
| Q4 FY2023 | Dec 31, 2023 | -$24.52M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.05M | – |
| Q1 FY2023 | Mar 31, 2023 | $123.06M | +257.8% |
| Q4 FY2022 | Dec 31, 2022 | -$13.18M | -221.5% |
| Q3 FY2022 | Sep 30, 2022 | -$16.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.73M | – |
| Q1 FY2022 | Mar 31, 2022 | $34.39M | – |
| Q4 FY2021 | Dec 31, 2021 | $10.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.94M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.67M | – |
| Q4 FY2020 | Dec 31, 2020 | -$25.53M | – |
| Q3 FY2020 | Sep 30, 2020 | -$29.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$23.08M | – |
| Q1 FY2020 | Mar 31, 2020 | -$30.31M | -124.4% |
| Q4 FY2019 | Dec 31, 2019 | -$26.74M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.75M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.62M | – |
| Q1 FY2019 | Mar 31, 2019 | $124.06M | +163.9% |
| Q4 FY2018 | Dec 31, 2018 | -$24.87M | – |
| Q3 FY2018 | Sep 30, 2018 | -$18.50M | – |
| Q2 FY2018 | Jun 30, 2018 | -$23.83M | – |
| Q1 FY2018 | Mar 31, 2018 | $47.00M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.00M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.30M | – |
| Q2 FY2017 | Jun 30, 2017 | -$16.80M | – |
| Q1 FY2017 | Mar 31, 2017 | -$17.24M | – |
| Q4 FY2016 | Dec 31, 2016 | -$16.96M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.69M | – |
See a number that looks wrong?